MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours

Richard Wilson, Mark Middleton, Jennifer Houlden, Sandra Van Schaeybroeck, Christian Rolfo, Elena Elez, Julien Taieb, Thierry Andre, alberto Bardelli, Pierre Laurent=puig, Josef Tabernero, Marc Peeters, Tim Maughan, C Roberts, Sharon Love, Mark Lawler, Manuel Salto-Tellez, Margaret Grayson, Vlad Popovici, Federica Di Nicolantonio

Research output: Contribution to journalMeeting abstract

Abstract

Background RAS activating mutations occur in ∼55% of metastatic (m) CRC. RASMT and >50% of RASWT mCRC patients (pts) do not benefit from anti-EGFR antibodies. c-MET is overexpressed in ∼50-60%, amplified in ∼2-3% and mutated in ∼1-3% of mCRC. Preclinical data support the clinical evaluation of MEK1/2 and METi, in particular in RASMT tumours and RASWT with aberrant c-MET expression. The primary aim of the phase I study was to establish the maximum tolerated dose (MTD) and assess safety/toxicity profile of PD-0325901 MEKi & crizotinib METi in pts with advanced solid tumours using NCI CTCAE V4.03. Methods A single arm, open-label phase I trial of PD-0325901 with crizotinib was performed in pts with advanced solid tumours, measurable disease, ECOG PS 0-1 and adequate end organ function. Pts received oral PD-0325901 BD (days 1-21 every 28 days) at doses of 2 - 8mg BD with oral crizotinib continuously at 250mg OD or 200mg BD, using a rolling 6 design. Crizotinib started after a 1 week lead-in with PD-0325901. Blood samples for pharmacokinetics, pERK and soluble c-MET levels and skin biopsies for pERK levels were collected. Results Between 12/2014 and 11/2015 we enrolled 25 pts; Male (13), Female (12). Median age 63 yrs (range 36-78). MTD was defined at the highest dose; crizotinib: 200mg BD continuously; PD-0325901: 8mg BD days 1-21 every 28 days. 1 of 6 patients exhibited dose-limiting toxicity (fatigue) at this dose level. The 25 pts received a total of 52 cycles. Drug-related adverse events were in keeping with single agent toxicity profiles, including rash, diarrhoea, fatigue, nausea, hypoalbuminemia and visual disturbances. Best clinical response was stable disease at the end of cycle 2, in 4/25 evaluable pts. Conclusions MEK/METi can be given together at pharmacologically active doses. MTD for the PD-0325901/crizotinib combination was 8mg BD (days 1-21) and 200mg BD continuously in a 28 day cycle. The combination is now being explored further with an alternate MEKi before expansion into RASMT and RASWT CRC with aberrant c-MET expression. EudraCT registry number: 2014-000463-40.
Original languageEnglish
JournalAnnals of Oncology
DOIs
Publication statusPublished - 08 Oct 2016

Fingerprint Dive into the research topics of 'MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours'. Together they form a unique fingerprint.

  • Cite this

    Wilson, R., Middleton, M., Houlden, J., Van Schaeybroeck, S., Rolfo, C., Elez, E., Taieb, J., Andre, T., Bardelli, A., Laurent=puig, P., Tabernero, J., Peeters, M., Maughan, T., Roberts, C., Love, S., Lawler, M., Salto-Tellez, M., Grayson, M., Popovici, V., & Di Nicolantonio, F. (2016). MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. Annals of Oncology. https://doi.org/10.1093/annonc/mdw370